Pharmafile Logo
Pharmafocus logo
Advanced Search

Lucentis

Showing 15 posts of 54 posts found.

Lucentis image

Lucentis approved in China

January 18, 2012
Sales and Marketing China, Galvus, Lucentis, Novartis, em, emerging markets

Novartis’ eye treatment Lucentis has gained approval in China, and the firm has also launched its diabetes drug Galvus in …

News
Lucentis picture

NICE rejects Lucentis in diabetic macular oedema

November 29, 2011
Sales and Marketing Lucentis, NICE

NICE has rejected Novartis’ Lucentis for diabetic macular oedema. NICE has not recommended Lucentis (ranibizumab) for the treatment of diabetic …

News
Lucentis image

Lucentis not backed by NICE for new licence

November 24, 2011
Sales and Marketing Lucentis, NICE, Novartis, Ozurdex

NICE has not recommended Novartis’ eye disease drug Lucentis due to ‘gaps and uncertainties’ in the manufacturer’s submission. In draft …

News
Eylea picture

Lucentis rival gains US approval

November 22, 2011
Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche

A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …

News
Novartis

Novartis cuts Lucentis price amid growing pressure

October 7, 2011
Sales and Marketing Lucentis, wet AMD

Novartis has been forced to cut the Swiss price of its eye drug Lucentis by 30% after sharp negotiations with …

News

NICE to review Lucentis decision

August 17, 2011
Sales and Marketing Lucentis, NICE, diabetic macular edema

NICE will allow an appeal against its decision not to recommend Novartis’s Lucentis for diabetic macular oedema. The appeal came …

News

NICE decides laser treatment better than Lucentis

July 18, 2011
Sales and Marketing Lucentis, NICE, Novartis

Novartis says it is “disappointed” with health watchdog NICE’s decision not to recommend Lucentis for the treatment of eye problems …

News

Bayer submits Lucentis rival for European approval

June 7, 2011
Sales and Marketing Bayer, Lucentis, Regeneron, VEGF Trap-Eye

Bayer Healthcare has submitted its new eye drug to European regulators for approval to treat age-related macular degeneration (wet AMD). …

News
Novartis HQ

Novartis eye drug wins wider European licence

June 6, 2011
Sales and Marketing Lucentis, Novartis

Novartis’ Lucentis has been approved in Europe to treat people suffering from vision loss due to macular oedema secondary to …

News

Government wrong to push for Avastin in eye disease, says charity

May 12, 2011
Research and Development, Sales and Marketing Lucentis, RNIB, avastin, wet AMD

The UK government’s pursuit of Avastin for use in ophthalmology is bad for patients, says the Royal National Institute of …

News
Roche's Avastin (bevacizumab)

Avastin as effective as Lucentis in eye disease

May 4, 2011
Research and Development Lucentis, avastin, off label, wet AMD

Roche’s cancer drug Avastin is as effective at treating wet AMD as Novartis’ Lucentis, which is licensed for the eye …

News

Bayer drug enters phase III for diabetic macular oedema

April 11, 2011
Sales and Marketing Bayer, Lucentis, ophthalmology

Bayer and partner Regeneron have begun late stage trials for their VEGF Trap Eye candidate for diabetic macular oedema. The …

News

NICE rejects Lucentis for diabetic oedema

March 4, 2011
Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab

NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …

News

Novartis becomes global eye health leader as Alcon deal finalised

December 15, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Alcon, Lucentis, Novartis, eye care, eye health, ophthalmology

Novartis’ 11-month standoff with Alcon shareholders has ended, allowing it to acquire all the remaining shares in the ophthalmology firm. …

News
Age-related macular degeneration (Wet AMD)

Bayer’s challenger to Lucentis shows promise

November 22, 2010
Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD

Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026